

TABLE S3 Observed deaths and SMRs among test participants and controls, and RRs of mortality in test participants compared with controls, for 27 distinct types of cancer. For leukaemia the whole follow-up period and the period 2 to 25 years after start of first test participation are considered, and for other specific cancers the period more than 10 years after start of first test participation is considered

Type of cancer (ICD 9 th Revision Codes)	Test participants		Controls		Mortality rate in test participants relative to controls			
	Observed deaths	SMR	Observed deaths	SMR	RR	90% CI	Probability ^a One sided	Probability ^b Two sided
Cancer of the tongue, mouth and pharynx (141, 143-149)	31	119	40	145	0.82	0.54, 1.26	0.25	0.47
Cancer of the oesophagus (150)	74	102	83	107	0.96	0.73, 1.26	0.43	0.86
Cancer of stomach (151)	90	80	91	76	1.06	0.82, 1.37	0.37	0.73
Cancer of large intestine and rectum (153, 154 excl. 154.3, 159.0)	172	94	174	89	1.05	0.87, 1.26	0.36	0.72
Cancer of liver (155)	24	116	17	77	1.51	0.86, 2.68	0.13	0.21
Primary liver cancer (155.0)	12	103	13	105	0.99	0.47, 2.05	0.57	1.00
Cancer of gallbladder (156)	2	31	5	72	0.39	0.06, 1.85	0.22	0.28
Cancer of pancreas (157)	72	104	72	98	1.04	0.78, 1.39	0.44	0.88
Cancer of larynx (161)	19	119	24	142	0.87	0.50, 1.50	0.38	0.66
Cancer of lung (162, 163)	466	86	517	89	0.97	0.87, 1.08	0.31	0.61
Cancer of bone (170)	2	61	1	30	2.11	0.19, 44.14	0.48	0.62
Cancer of connective and soft tissue (171)	5	72	3	42	1.79	0.45, 7.75	0.32	0.49
Malignant melanoma (172)	28	171	27	159	1.09	0.68, 1.76	0.43	0.79
Other skin cancer (173)	2	54	0	0	1.09	0.68, 1.76	0.17	0.17
Cancer of prostate (185)	106	116	97	97	1.20	0.94, 1.53	0.11	0.22
Cancer of testis (186)	5	95	3	61	1.60	0.39, 7.13	0.39	0.71
Cancer of bladder (188, 189.3-189.9)	50	94	34	59	1.64	1.11, 2.42	0.017	0.026
Cancer of kidney (189.0-189-2)	43	110	59	142	0.78	0.55, 1.11	0.13	0.26
Tumours of central nervous system (191, 192, 224, 225, 239.6)	63	102	66	103	0.99	0.73, 1.35	0.52	0.97
Cancer of thyroid (193)	1	37	1	35	1.00	0.04, 27.44	0.76	1.00
Cancer of adrenals (194.0) ^c	2	201	2	194	1.12	0.14, 8.76	0.65	1.00
Hodgkin's disease (201)	6	63	9	95	0.73	0.27, 1.92	0.36	0.62
Non-Hodgkin's lymphoma (200, 202.0-202.3, 202.5-202.9)	41	93	44	95	0.92	0.62, 1.35	0.39	0.74
Multiple myeloma (203 excl 203.1, 238.6) ^d	21	93	18	75	1.32	0.74, 2.37	0.24	0.43
Leukaemia: whole follow up period	45	98	33	68	1.45	0.96, 2.17	0.069	0.14
Leukaemia: 2-25 yrs (202.4, 203.1, 204-208)	20	123	6	32	3.38	1.45, 8.25	0.0056	0.0072
Leukaemia excluding CLL: whole follow up period	40	106	23	58	1.83	1.15, 2.93	0.015	0.027
Leukaemia excluding CLL: 2-25 yrs (202.4, 203.1, 204.0, 204.2-207.7 207.9-208.9)	18	123	6	36	2.99	1.26, 7.41	0.014	0.019
Polycythaemia vera (238.4) ^e	1	92	2	173	0.54	0.03, 5.84	0.52	1.00
Other specified neoplasms (140-239 excl, above, 196-199 & 239)	27	84	28	83	1.08	0.67, 1.75	0.44	0.79
Unspecified neoplasms (196-199, 239, excl. 239.6)	100	91	134	114	0.83	0.66, 1.04	0.086	0.17
All neoplasms excluding non-melanoma skin cancer (140-172, 174-239)	1491	94	1582	93	1.01	0.95, 1.07	0.39	0.78
All neoplasms (140-239)	1493	94	1582	93	1.01	0.95, 1.08	0.37	0.75

Notes

- (a) One-sided test that the RR is greater than unity (if estimated to be greater than or equal to one), or less than unity (if estimated to be less than one).
- (b) Two-sided test that the RR is different from unity.

- (c) Cancers of the adrenal glands are included only from 1958 in the comparison with national rates; no deaths in participants and none in controls occurred before this.
- (d) The observed numbers of deaths and RR are unchanged for the wider definition of multiple myeloma (ICD 9th revision codes 203.0, 203.1, 238.6 and 273.1).
- (e) Polycythaemia vera is included only from 1968 in the comparison with national rates; no deaths in participants and none in controls occurred before this.